[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2020002559A - Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. - Google Patents

Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.

Info

Publication number
MX2020002559A
MX2020002559A MX2020002559A MX2020002559A MX2020002559A MX 2020002559 A MX2020002559 A MX 2020002559A MX 2020002559 A MX2020002559 A MX 2020002559A MX 2020002559 A MX2020002559 A MX 2020002559A MX 2020002559 A MX2020002559 A MX 2020002559A
Authority
MX
Mexico
Prior art keywords
protein conjugates
carrier protein
serotypes
polysaccharide
pneumococcal polysaccharides
Prior art date
Application number
MX2020002559A
Other languages
English (en)
Inventor
Chitrananda Abeygunawardana
Richard J Porambo
Luwy Kavuka Musey
Michael J Kosinski
Yadong Adam Cui
Julie Marie Skinner
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of MX2020002559A publication Critical patent/MX2020002559A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0003—General processes for their isolation or fractionation, e.g. purification or extraction from biomass
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08H—DERIVATIVES OF NATURAL MACROMOLECULAR COMPOUNDS
    • C08H1/00—Macromolecular products derived from proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Sustainable Development (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)

Abstract

La presente invención proporciona polisacáridos capsulares de serotipos de Streptococcus pneumoniae identificados usando RMN. La presente invención proporciona además conjugados de polisacárido-proteína en los que los polisacáridos capsulares de uno o más de estos serotipos se conjugan con una proteína transportadora tal como CRM197. Los conjugados de polisacárido-proteína de uno o más de estos serotipos pueden incluirse en vacunas conjugadas neumocócicas multivalentes que tienen polisacáridos de múltiples serotipos adicionales de Steptococcus pneumoniae.
MX2020002559A 2017-09-07 2018-09-04 Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora. MX2020002559A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762555455P 2017-09-07 2017-09-07
PCT/US2018/049306 WO2019050814A1 (en) 2017-09-07 2018-09-04 ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER

Publications (1)

Publication Number Publication Date
MX2020002559A true MX2020002559A (es) 2020-07-13

Family

ID=65635315

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020002559A MX2020002559A (es) 2017-09-07 2018-09-04 Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
MX2022014850A MX2022014850A (es) 2017-09-07 2020-03-05 Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2022014850A MX2022014850A (es) 2017-09-07 2020-03-05 Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.

Country Status (10)

Country Link
US (6) US11491216B2 (es)
EP (1) EP3678655A4 (es)
JP (2) JP2020533437A (es)
KR (1) KR20200051003A (es)
CN (2) CN111065388A (es)
AU (2) AU2018328036B2 (es)
BR (1) BR112020004396A8 (es)
CA (1) CA3074706A1 (es)
MX (2) MX2020002559A (es)
WO (1) WO2019050814A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105934251A (zh) * 2014-01-21 2016-09-07 辉瑞大药厂 肺炎链球菌荚膜多糖及其缀合物
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
US11951165B2 (en) 2016-12-30 2024-04-09 Vaxcyte, Inc. Conjugated vaccine carrier proteins
CN110366428B (zh) 2016-12-30 2024-05-17 Vaxcyte公司 具有非天然氨基酸的多肽-抗原缀合物
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
AU2018225099B2 (en) 2017-02-24 2024-08-22 Merck Sharp & Dohme Llc Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
US11400162B2 (en) 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
US10729763B2 (en) 2017-06-10 2020-08-04 Inventprise, Llc Mixtures of polysaccharide-protein pegylated compounds
US11524076B2 (en) 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
CN111065388A (zh) * 2017-09-07 2020-04-24 默沙东公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
KR20200051005A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
WO2019050815A1 (en) * 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
CN116898959A (zh) 2017-09-07 2023-10-20 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
US20200330579A1 (en) * 2017-10-04 2020-10-22 Liffey Biotech Limited Saccharide-polypeptide conjugate compositions and methods of use thereof
EA202091382A1 (ru) 2017-12-06 2021-01-15 Мерк Шарп И Доум Корп. Композиции, содержащие конъюгаты полисахарид streptococcus pneumoniae с белком, и способы их применения
CN112041435B (zh) 2018-04-30 2024-05-31 默沙东有限责任公司 提供冻干的突变白喉毒素在二甲基亚砜中的均质溶液的方法
JP7506605B6 (ja) 2018-04-30 2024-07-16 メルク・シャープ・アンド・ドーム・エルエルシー 肺炎球菌莢膜多糖類担体タンパク質複合体の製造方法
AU2019341723B2 (en) 2018-09-23 2024-03-21 Biological E Limited Purified capsular polysaccharides of Streptococcus pneumoniae
EP3897705A2 (en) 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
IL295713A (en) * 2020-02-21 2022-10-01 Pfizer Isolation of saccharides
WO2022169787A1 (en) * 2021-02-04 2022-08-11 Merck Sharp & Dohme Llc Lipid nanoparticle adjuvant composition for pneumococcal conjugate vaccines
WO2024110839A2 (en) 2022-11-22 2024-05-30 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
WO2024116096A1 (en) 2022-12-01 2024-06-06 Pfizer Inc. Pneumococcal conjugate vaccine formulations

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2059693C (en) * 1991-01-28 2003-08-19 Peter J. Kniskern Polysaccharide antigens from streptococcus pneumoniae
CA2059692C (en) 1991-01-28 2004-11-16 Peter J. Kniskern Pneumoccoccal polysaccharide conjugate vaccine
US7955605B2 (en) * 2005-04-08 2011-06-07 Wyeth Llc Multivalent pneumococcal polysaccharide-protein conjugate composition
CA3165042A1 (en) * 2005-04-08 2006-10-19 Wyeth Multivalent pneumococcal polysaccharide-protein conjugate composition
CA2635208C (en) 2005-12-28 2018-03-20 The Uab Research Foundation Streptococcus pneumonia having a capsular polysaccharide repeating unit {>2)glucose 1(1>3) glucose 2 (1>3) rhamnose (1>3)ribitol (5>phosphate}
GB0703369D0 (en) * 2007-02-21 2007-03-28 Health Prot Agency Compositions Comprising Capsular Polysaccharides and Their Use as Vaccines
ES2493040T3 (es) * 2008-07-31 2014-09-11 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Uso de un péptido P4 de neumococos para potenciar la opsonofagocitosis en respuesta a un patógeno
TW201136603A (en) 2010-02-09 2011-11-01 Merck Sharp & Amp Dohme Corp 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
PL3170508T3 (pl) 2010-06-04 2020-04-30 Wyeth Llc Preparaty szczepionek
AR084158A1 (es) * 2010-12-10 2013-04-24 Merck Sharp & Dohme Formulaciones que mitigan la agregacion inducida por agitacion de composiciones inmunogenicas
US20150132339A1 (en) * 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
MX363511B (es) 2012-08-16 2019-03-26 Pfizer Proceso de glucoconjugación y composiciones.
CN103623401A (zh) * 2012-08-23 2014-03-12 北京科兴中维生物技术有限公司 多价肺炎球菌荚膜多糖-蛋白质共轭组合物及其制备方法
US11160855B2 (en) * 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CA3170344C (en) * 2014-01-21 2023-08-29 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
ES2701169T3 (es) * 2014-02-14 2019-02-21 Pfizer Conjugados glucoproteicos inmunogénicos
ES2793023T3 (es) * 2014-08-08 2020-11-12 Glaxosmithkline Biologicals Sa Células huésped modificadas y oligosacáridos híbridos para su uso en producción de bioconjugados
KR20240007690A (ko) * 2015-06-08 2024-01-16 세럼 인스티튜트 오브 인디아 프라이비트 리미티드 다당류-단백질 접합체의 흡착을 개선시키는 방법 및 그로부터 수득된 다가 백신 제제
RU2721128C2 (ru) * 2015-07-21 2020-05-18 Пфайзер Инк. Иммуногенные композиции, содержащие конъюгированные антигены капсульного сахарида, наборы, содержащие эти композиции, и их применения
US11058757B2 (en) 2016-03-31 2021-07-13 Pogona, LLC Saccharide-polypeptide conjugate compositions and methods of use thereof
US20190119313A1 (en) * 2016-04-14 2019-04-25 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Improved preparation of vaccines against streptococcus pneumoniae type 3
GB201610599D0 (en) * 2016-06-17 2016-08-03 Glaxosmithkline Biologicals Sa Immunogenic Composition
CN109415104A (zh) * 2016-06-30 2019-03-01 福特全球技术公司 用于框架安装式踏板节奏传感器的系统、方法和装置
WO2018144439A1 (en) 2017-01-31 2018-08-09 Merck Sharp & Dohme Corp. Methods for making polysaccharide-protein conjugates
KR102650073B1 (ko) 2017-01-31 2024-03-20 머크 샤프 앤드 돔 엘엘씨 스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
EP3585427A4 (en) 2017-02-24 2020-12-30 Merck Sharp & Dohme Corp. METHODS FOR IMPROVING THE FILTRABILITY OF POLYSACCHARIDE CONJUGATE WITH PROTEIN REACTIONS
US20200054740A1 (en) 2017-02-24 2020-02-20 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
WO2018156465A1 (en) 2017-02-24 2018-08-30 Merck Sharp & Dohme Corp. Polysaccharide-protein conjugates utilizing diphtheria toxin fragment b as a carrier
AU2018225099B2 (en) * 2017-02-24 2024-08-22 Merck Sharp & Dohme Llc Enhancing immunogenicity of Streptococcus pneumoniae polysaccharide-protein conjugates
US11400162B2 (en) * 2017-02-24 2022-08-02 Merck Sharp & Dohme Llc Processes for the formulation of pneumococcal polysaccharides for conjugation to a carrier protein
GEP20227408B (en) * 2017-05-05 2022-08-25 Serum Institute Of India Pvt Ltd Method for removal of impurities from bacterial capsular polysaccharide based preparations
GB201711635D0 (en) * 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
GB201711637D0 (en) * 2017-07-19 2017-08-30 Glaxosmithkline Biologicals Sa Immunogenic composition
US20200360500A1 (en) 2017-08-16 2020-11-19 Merck Sharp & Dohme Corp. Pneumococcal conjugate vaccine formulations
CN116898959A (zh) * 2017-09-07 2023-10-20 默沙东有限责任公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
KR20200051005A (ko) 2017-09-07 2020-05-12 머크 샤프 앤드 돔 코포레이션 폐렴구균 폴리사카라이드 및 면역원성 폴리사카라이드-담체 단백질 접합체에서의 그의 용도
CN111050794A (zh) 2017-09-07 2020-04-21 默沙东公司 将肺炎球菌多糖与载体蛋白缀合的配制方法
CN111065388A (zh) * 2017-09-07 2020-04-24 默沙东公司 肺炎球菌多糖及其在免疫原性多糖-载体蛋白缀合物中的用途
US11524076B2 (en) * 2017-09-07 2022-12-13 Merck Sharp & Dohme Llc Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
WO2019050815A1 (en) 2017-09-07 2019-03-14 Merck Sharp & Dohme Corp. ANTI-PNEUMOCOCCAL POLYSACCHARIDES AND THEIR USE IN IMMUNOGENIC CONJUGATES POLYSACCHARIDE-PROTEIN CARRIER
KR20200077538A (ko) 2017-10-25 2020-06-30 머크 샤프 앤드 돔 코포레이션 아주반트 첨가된 백신
EA202091382A1 (ru) * 2017-12-06 2021-01-15 Мерк Шарп И Доум Корп. Композиции, содержащие конъюгаты полисахарид streptococcus pneumoniae с белком, и способы их применения
CN112074294A (zh) * 2018-04-30 2020-12-11 默沙东公司 从冻干球生产肺炎链球菌荚膜多糖载体蛋白缀合物的方法
EP3897705A2 (en) * 2018-12-19 2021-10-27 Merck Sharp & Dohme Corp. Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
TW202116352A (zh) * 2019-07-18 2021-05-01 南韓商賽特瑞恩股份有限公司 包含多價肺炎球菌多醣-蛋白共軛物的免疫組成物、醫藥組成物及其用途
EP4192499A4 (en) * 2020-08-10 2024-09-25 Inventprise Inc MULTIVALENT PNEUMOCOCCAL GLYCOCONJUGATE VACCINES CONTAINING AN EMERGING 24F SEROTYPE

Also Published As

Publication number Publication date
AU2018328036A1 (en) 2020-03-19
RU2020112312A3 (es) 2022-03-23
US20230029424A1 (en) 2023-01-26
US20230107713A1 (en) 2023-04-06
US20230075760A1 (en) 2023-03-09
KR20200051003A (ko) 2020-05-12
AU2024201479A1 (en) 2024-03-28
US11491216B2 (en) 2022-11-08
EP3678655A4 (en) 2021-05-05
AU2018328036B2 (en) 2024-03-07
JP2023113922A (ja) 2023-08-16
EP3678655A1 (en) 2020-07-15
CN111065388A (zh) 2020-04-24
RU2020112312A (ru) 2021-10-07
US20230094548A1 (en) 2023-03-30
US20200330578A1 (en) 2020-10-22
JP2020533437A (ja) 2020-11-19
CA3074706A1 (en) 2019-03-14
WO2019050814A1 (en) 2019-03-14
CN117736348A (zh) 2024-03-22
MX2022014850A (es) 2022-12-15
BR112020004396A2 (pt) 2020-09-08
US20230041441A1 (en) 2023-02-09
BR112020004396A8 (pt) 2023-01-31

Similar Documents

Publication Publication Date Title
MX2022014850A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
MX2022009927A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
MX2022009928A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
MX2020002555A (es) Polisacaridos neumococicos y su uso en conjugados de polisacarido inmunogenico con proteina transportadora.
GEP20227420B (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
MX2023001948A (es) Inmunogenicidad mejorada de conjugados de polisacarido-proteina de streptococcus pneumoniae.
PE20161095A1 (es) Composiciones inmunogenicas que comprenden antigenos de sacaridos capsulares conjugados y uso de los mismos
GEP20247633B (en) Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
CU24660B1 (es) Composiciones de vacunas multivalentes que comprenden conjugados de polisacárido-proteína de streptococcus pneumoniae utilizando proteínas portadoras psaa y crm197
PH12019500240A1 (en) Multivalent pneumococcal polysaccharide-protein conjugate composition
CY1123838T1 (el) Πολυσθενες εμβολιο πνευμονιοκοκκικου συζευγματος
AR109290A1 (es) Composición conjugada neumocócica multivalente de polisacárido y proteína
MX2023012389A (es) Vacuna.
EA200901578A1 (ru) Вакцина, содержащая конъюгаты капсульных полисахаридов streptococcus pneumoniae
TN2012000377A1 (en) 15-valent pneumococcal polysaccharide-protein conjugate vaccine composition
CO2021007863A2 (es) Vacuna conjugada polisacárido-proteína neumocócica multivalente
PH12019500377A1 (en) Composition comprising multivalent capsular polysaccharide-transport protein and use thereof
AR109377A1 (es) Composición conjugada neumocócica multivalente de polisacárido y proteína